08 Dec Nordion and General Atomics welcome US National Nuclear Security Administration Phase II funding for new, reliable source of molybdenum-99
“We are pleased NNSA has elected to continue funding this important project and have full confidence that, with our partners Nordion and MURR®, we will develop the capability to commercially produce Mo-99 using GA’s LEU-based selective gas extraction technology. Our Phase I results show that the product meets Nordion’s stringent specification requirements for use in their existing infrastructure,” added Kathy Murray, GA’s Mo-99 Project Manager.
A medical isotope is a safe radioactive substance used by health professionals to assist in the diagnosis of approximately 50 million patients in North America and around the world every year. The most important of these is technetium-99m (Tc-99m), which is derived from molybdenum-99 (Mo-99) and used in more than 80 percent of all nuclear medicine procedures.
Nordion is a leading provider of medical isotopes and gamma technologies used for the prevention, diagnosis and treatment of disease and infection. Nordion’s products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion supplies products to approximately 500 customers across more than 40 countries around the globe, and is a standalone business within Sterigenics International LLC, the leading global provider of contract sterilization and lab services for the medical device industry, the world’s leading supplier of Co-60 and a leading supplier of medical isotopes. Sterigenics International, LLC is the only vertically integrated sterilization company in the world. Learn more at www.nordion.com and follow us on Twitter at @NordionInc.
San Diego-based General Atomics is committed to developing energy innovations and advanced technologies with world-changing potential. The scientists and engineers of GA’s Energy Group are pushing the frontier of scientific discovery to produce safe, sustainable and economic solutions to global challenges in energy, medical imaging and next generation computing. Learn more about General Atomics at www.GA.com.
University of Missouri Research Reactor (MURR)
The University of Missouri Research Reactor Center (MURR®) has a long history of safe reliability. With its 10 MW reactor and a 6½-days-per-week; 52 week per year operating schedule, MURR supports research and education while also providing short-lived isotopes for medical applications. MURR provides a range of radioisotopes that help medical professionals diagnose and treat many diseases, including cardiovascular disease and cancer. The nation’s largest university research reactor also supports undergraduate and graduate education programs that train the next generation of nuclear engineers and chemists. For more information on University of Missouri Research Reactor Center please visit: http://www.murr.missouri.edu/.
For further information:
Nordion, Paul Monlezun, 613-222-7184, mailto:[email protected]
General Atomics, Zabrina Johal, (858) 455-4004, mailto:[email protected]